se of memantin in treatment of adult with attention deficit hyperactivity disorder
Phase 3
- Conditions
- Adult ADHD (Attention-deficit hyperactivity disorder ).Disturbance of activity and attention
- Registration Number
- IRCT2016053028182N1
- Lead Sponsor
- Kurdistan University of Medical science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
receiving DSM-IV-TR diagnostic criteria for ADHD; the age range of 18 to 45 years old; not using any psychiatric drugs at least 2 weeks before the research. Exclusion criteria: having mental retardation; having any psychiatric disorders except Oppositional Defiant disorder; allergic history to Memantine; having serious disorder like heart disease; uncontrolled Seizure disorder; individuals with Systolic blood pressure above 125 mmHg or resting pulse under 60 or having above 115 beats per minute: Pregnant and lactating women
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in hyperactivity symptome. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conners' Adult ADHD Rating Scales–Self-Report.;Improvement in Impulsivity symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conners' Adult ADHD Rating Scales–Self-Report.;Improvement in Attention-deficit symptoms. Timepoint: Baseline, third and sixth weeks after intervention. Method of measurement: Conners' Adult ADHD Rating Scales–Self-Report.
- Secondary Outcome Measures
Name Time Method Drug side effects. Timepoint: third and sixth weeks after intervention. Method of measurement: checklist of side effects.;Efficacy in more than 50% of reduction in ADHD diagnostic rating scale. Timepoint: six weeks after treatment. Method of measurement: Parent interview.